Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 679

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 679
---
 between Viral Gene and the Company dated as of April 10, 2020.

(b) Section 4.1(a)(iv) — Conditions to the Obligations of the Parties at Closing (Net Tangible Assets) . Section 4.1(a)(iv) of the BCA is hereby deleted in its entirety and replaced with “Reserved.”

(c) Section 4.1(b)(iii) — Conditions to Obligations of SPAC . Section 4.1(b)(iii) of the BCA is hereby amended and restated in its entirety to read as follows:

“(iii) Material Adverse Effect . Except as disclosed in the Proxy/Registration Statement, since the Effective Date, there has been no Material Adverse Effect which is continuing and uncured.”

(d) Sections 4.1(b) — Conditions to Obligations of SPAC . Each of Sections 4.1(b)(ix)(B) and (xii) of the BCA is hereby deleted in its entirety and replaced with “Reserved.”

(e) Sections 4.1(b) — Conditions to Obligations of SPAC . A new Section 4.1(b)(xiv) shall be inserted into the BCA and read as follows:

“(xiv) Acknowledgement of Viral Gene. SPAC shall have received an acknowledgement from Viral Gene stating that the obligations of the parties thereto, including ParentCo and the Company, under, or pursuant to, the Viral Gene Assignment have been satisfied or terminated and that no obligations of any party thereto, including ParentCo and the Company, under the Viral Gene Assignment remain outstanding.”

(f) Section 5.11(a) — Intellectual Property . Section 5.1(a) of the BCA is hereby amended and restated in its entirety to read as follows:

“(a) Pursuant to the InnoBation License, the Company has been granted worldwide Intellectual Property rights to the Products as set forth in each license.”

<div align='center'>A-90</div>

TABLE OF CONTENTS

(g) Section 6.8 — Listing . Section 6.8 of the BCA is hereby amended and restated in its entirety to read as follows:

“The issued and outstanding SPAC Class A Shares are registered pursuant to Section 12(b) of the Securities Exchange Act. As of the Effective Date, there is no Proceeding or investigation pending or, to the Knowledge of SPAC, threatened against SPAC by the NASDAQ or the SEC